A Phase 1/2 interventional study of Eltrombopag 25 MG and Prednisolone in Primary Immune Thrombocytopenia, sponsored by Renata PLC. Recruiting at 1 site in Bangladesh. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by Renata PLC · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 7th largest by planned enrollment, is one of 4 that started in 2025, is the only one in phase 1/2, and was the 31st registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Sohag University · Sites in Egypt
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
Novartis Pharmaceuticals
Ages 5–17
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 12–75
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 40 across the 36 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Renata PLC as lead sponsor.
Renata PLC has 1 study filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
1 of the studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07189910Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be a double-blind, placebo-control, randomized clinical trial conducted in the Department of Hematology, DMCH for one year. This study will help to establish the role of eltrombopag as a first-line therapy in newly diagnosed ITP. Newly diagnosed ITP patients will be selected after meeting inclusion and exclusion criteria, they will be thoroughly informed about the study, used drugs, randomization, risks, benefits, and follow-up. If they agree to participate, their consent will be taken and they will be enrolled in the study. A detailed history and clinical exam will be done. Primary investigation will be - CBC PBF, RBS, ANA, TSH, Anti H. pyloriIgG, Anti-HCV, APTT, and BMS (if indicated). The main outcome variable will be platelet count and number of spontaneous bleeding. Total sample size would be 100 (50 in each group). Enrolled patients would be divided into two groups (1:1) by block randomization. One group will get Eltrombopag\& Prednisolone and other group will get Eltrombopag\& Placebo. Researchers or any one related to the study in DMCH, patients \& their attendants, no one will know which patient will get placebo or eltrombopag. Only a respectable third party will know the information. A patient would be followed up on 1st, 2nd and 4th week of starting therapy. Patients would be evaluated in every follow up by history, physical examination and investigation. History of any spontaneous bleeding event, any discomfort or new symptoms science last follow up will be noted. General examination will be performed in every follow-up. CBC, RBS, ALT, AST, creatinine will be done in every follow-up. Data will be collected on a pre-designed case record form and will be collected through face-to-face interviews, physical examination, and laboratory reports. After data collection data will be edited, cleaned, and prepared for analysis at the end of the study. The statistical analysis will be conducted using SPSS version 25 statistical software. The results of the study will be published in national and international journals.
Study procedure After meeting inclusion and exclusion criteria patients will be thoroughly informed about the study, used drugs, randomization, risk and benefits, follow up. If they agree to participate in the study, their consent for this study will be taken and they will be enrolled in the study.
Detail history and clinical exam will be done. Key points are- History of spontaneous bleeding in last month, History of vaccination, History of recent viral infection, fever, Presence of organomegaly.
Primary investigation will be- CBC PBF, RBS, ANA, TSH, Anti H. pyloriIgG, Anti-HCV, APTT, BMS (if indicated)
NB:
Blinding and placebo control: It will be a double-blind study. Researchers nor participants will know who is getting placebo/eltromopag. One group will get Prednisolone \& Eltrombopag and another group will get Prednisolone \& Placebo. Eltrombopag, Prednisolone and Placebo will be provided by Renata Limited Bangladesh and patient will get at free of costs. Placebo will have same size, shape, color, markings, taste, smell and packaging like Eltrombopag. Eltrombopag and placebo will be provided in separate color-coded box marked-A (red) or B (green). Group A and Group B participants will be given colored cards (red and green) for identification. They will receive tablets from marked box. Researchers or any one related to the study in DMCH, patients \& their attendants no will know which box contain placebo or eltrombopag. Only respectable person of Renata limited will know the information. The team who knows the information will be head by their CEO. At the end point all data will be submitted to the team who know about placebo.
Experimental Group - Eltrombopag\& Prednisolone Control Group - Prednisolone and Placebo Dose- Prednisolone 1mg/kg/day for 28 days Eltrombopag/Placebo 25mg/day for 28 days Follow Up- Follow up at the end of 1st week, 2nd week and 4th week Patient would be evaluated in every follow up by history, physical examination and investigation. History of any spontaneous bleeding event, any discomfort or new symptoms science last follow up. General examination will be performed in every follow up. CBC, RBS, ALT, AST and creatinine will be done in every follow up.
Primary End Point-28 days after starting therapy. Complete Response is expected after 28 days of therapy.
Patient would continue therapy and follow up in OPD but would not be included in the study.
Supportive care and rescue- A Data and Safety Monitoring Board (DSMB) will be formed which will include two members of NREC, one hematologist and one medicine specialist. Any adverse event (Drugs side effects- headache, weight gain, changes in liver enzymes, high blood sugar) or serious adverse event (grade 3 or grade 4 bleeding, hospitalization, thrombosis) will be delt with proper medical care.
If any patient shows no response within 14 days and has grade 3 or 4 bleeding rescue with methyl prednisolone or IV Ig would be given and discontinued from study. If group A patient reaches platelet count >400x109\L, eltrombopag will be stopped.
Data Analysis After data collection data will be edited, cleaned and prepared for analysis at the end of the study. At the end of the study, all data will be submitted to the team who know about placebo/eltrombopag. The statistical analysis will be conducted using SPSS (statistical package for the social science) version 25 statistical software. The findings of the study will be presented by frequency and percentage in tables. Means and standard deviations for continuous variables and proportion for categorical variables will be used to describe the characteristics of the total sample. Association between two qualitative variables will be assessed by Chi-square test, where p\<0.05 with 95% confidence level will be considered as significant. Appropriate statistical tests will be done to interpret the findings of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eltrombopag + Prednsolone
Drug: Eltrombopag 25 MG · Drug: Prednisolone
Placebo + Prednisolone
Drug: Prednisolone
Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Also known as: Prednisolone
Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Also known as: Placebo
Changes in Platelet count
Compare change in platelet count in two groups
Time frame: 28 days (platelet count will be measured at the end of 1st, 2nd and 4th week)
Spontaneous bleeding
Compare number of Spontaneous bleeding in two groups
Time frame: 28 days (Spontaneous bleeding episodes will be noted by face to face interview at the end of 1st, 2nd and 4th week)
Changes in hemoglobin
Compare change in hemoglobin count in two groups
Time frame: 28 days (hemoglobin will be measured at the end of 1st, 2nd and 4th week)
Changes in Total WBC count
Compare change in total WBC count in two groups
Time frame: 28days (WBC count will be measured at the end of 1st, 2nd and 4th week)
Change in ALT
Compare change in ALT in two groups
Time frame: 28 days ( ALT will be measured at the end of 1st, 2nd and 4th week)
Change in AST
Compare change in AST
Time frame: 28 days ( AST will be measured at the end of 1st, 2nd and 4th week)
Change in S.Createnine
Compare change in S.Createnine in two groups
Time frame: 28 days (S.Createnine will be measured at the end of 1st, 2nd and 4th week)
Change in RBS
Compare change RBS in two groups
Time frame: 28 days (RBS will be measured at the end of 1st, 2nd and 4th week)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Sharing via E-Mail of PI and will be also available in DMC database.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: From the starting of data collection to upto one year of the end of the study.
Access criteria: Via submitting request to PI via EMail
Started Feb 2025 (actual). Primary completion is estimated for Aug 2025, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag
Purpura, Thrombocytopenic, Idiopathic →